The current ENGN market cap is 392.23M. The company's latest EPS is CAD -2.2927 and P/E is -3.93.
Quarter End | Jul 2023 |
---|---|
CAD ($) | |
Total Revenue | 0 |
Operating Income | -72.1M |
Net Income | -72.49M |
Year End October 30 2023 | 2023 |
---|---|
CAD ($) | |
Total Revenue | 0 |
Operating Income | -26.06M |
Net Income | -99.92M |
Quarter End | Jul 2023 |
---|---|
CAD ($) | |
Total Assets | 7k |
Total Liabilities | 72.49M |
Total Equity | -72.48M |
Year End October 30 2023 | 2023 |
---|---|
CAD ($) | |
Total Assets | 86.96M |
Total Liabilities | 14.47M |
Total Equity | 72.49M |
Market Cap | 392.23M |
Price to Earnings Ratio | -3.93 |
Price to Sales Ratio | 0 |
Price to Cash Ratio | 4.81 |
Price to Book Ratio | 5.41 |
Dividend Yield | - |
Shares Outstanding | 43.58M |
Average Volume (1 week) | 233.55k |
Average Volume (1 Month) | 92.73k |
52 Week Change | -47.03% |
52 Week High | 43.00 |
52 Week Low | 6.69 |
Spread (Intraday) | 0.8 (8.79%) |
Company Name | enGene Holdings Inc |
Address |
suite 2600, three bentall centre, 595 burrard street vancouver, british columbia V7X 1L3 |
Website | https:// |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.